Key Takeaways
- • EBOS Group abandoned a A$3.75 billion acquisition of TPG Capital-backed Greencross in April 2026 due to weak investor demand for a planned A$2 billion capital raise at a 12% discount, causing EBOS shares to initially drop 7%.
- • Sydney-based buyout firms (identified as Adamantem Capital in supplemental sources) are now in advanced talks to acquire Green Cross Health's general practice clinics segment, representing a separate carve-out from the broader pets-and-vets business.
- • Greencross operates 160 veterinary clinics and 230 retail stores across Australia and New Zealand under the Petbarn, City Farmers, and Animates banners; Green Cross Health separately owns medical centres and pharmacy brands including The Doctors, Unichem, and Life Pharmacy.
- • TPG Capital's ownership of Greencross dates to a 2019 acquisition for A$675 million, with the firm subsequently selling down 45% to AustralianSuper and a Canadian pension fund in 2022 before exploring multiple exit options including IPO and now strategic sale.
- • The failed EBOS transaction signals deteriorating market appetite for large-cap healthcare and consumer acquisitions in the Australian market, with capital raise dilution concerns driving investor resistance.
Summary
Sydney-based private equity firms are in talks to acquire the general practice clinic business from Green Cross Health, marking a significant shift in the market for Australian primary care consolidation. The move comes amid broader volatility in healthcare sector M&A, highlighted by the recent collapse of a competing transaction in the same market.
The most significant recent event in this space occurred in April 2026, when EBOS Group, Australasia's largest pharmaceutical wholesaler, shelved a A$3.75 billion bid for TPG Capital-backed Greencross after encountering severe headwinds in its planned A$2 billion capital raise. EBOS intended to offer shares at a 12% discount, a dilution level that proved unpalatable to its investor base. With EBOS commanding a NZ$7.4 billion market capitalization, the scale of the capital raising was deemed highly dilutive. Macquarie Group and UBS were underwriting the failed transaction. EBOS shares initially declined 7% on the announcement before recovering to a 3-4% loss, signaling that despite perceived strategic merit, the financing execution could not overcome investor skepticism.
Greencross itself, owned by TPG Capital since 2019 (original acquisition price A$675 million), operates a substantial network comprising 160 veterinary clinics and 230 retail locations across Australia and New Zealand, trading under the Petbarn, City Farmers, and Animates banners. TPG subsequently sold down 45% to AustralianSuper and a Canadian pension fund in 2022, indicating the private equity sponsor had already begun exploring strategic alternatives including potential public listing and now selective asset sales.
The emergence of Sydney buyout firms pursuing the Green Cross Health general practice segment separately suggests a more targeted acquisition strategy than the failed EBOS transaction. This represents a carve-out of the primary care medical centres business from the broader pets-and-veterinary operations, reflecting investor preference for smaller, more manageable transactions in the current capital environment. Green Cross Health, which owns The Doctors medical centre network alongside Unichem and Life Pharmacy brands, has maintained a position of non-confirmation regarding sale rumors, though the advanced negotiations by Adamantem Capital and other Sydney-based buyers suggest material momentum.
The broader context indicates consolidation fatigue among large institutional capital providers for healthcare M&A in Australia, while smaller private equity firms remain actively engaged in segmented acquisitions within the sector.
The most significant recent event in this space occurred in April 2026, when EBOS Group, Australasia's largest pharmaceutical wholesaler, shelved a A$3.75 billion bid for TPG Capital-backed Greencross after encountering severe headwinds in its planned A$2 billion capital raise. EBOS intended to offer shares at a 12% discount, a dilution level that proved unpalatable to its investor base. With EBOS commanding a NZ$7.4 billion market capitalization, the scale of the capital raising was deemed highly dilutive. Macquarie Group and UBS were underwriting the failed transaction. EBOS shares initially declined 7% on the announcement before recovering to a 3-4% loss, signaling that despite perceived strategic merit, the financing execution could not overcome investor skepticism.
Greencross itself, owned by TPG Capital since 2019 (original acquisition price A$675 million), operates a substantial network comprising 160 veterinary clinics and 230 retail locations across Australia and New Zealand, trading under the Petbarn, City Farmers, and Animates banners. TPG subsequently sold down 45% to AustralianSuper and a Canadian pension fund in 2022, indicating the private equity sponsor had already begun exploring strategic alternatives including potential public listing and now selective asset sales.
The emergence of Sydney buyout firms pursuing the Green Cross Health general practice segment separately suggests a more targeted acquisition strategy than the failed EBOS transaction. This represents a carve-out of the primary care medical centres business from the broader pets-and-veterinary operations, reflecting investor preference for smaller, more manageable transactions in the current capital environment. Green Cross Health, which owns The Doctors medical centre network alongside Unichem and Life Pharmacy brands, has maintained a position of non-confirmation regarding sale rumors, though the advanced negotiations by Adamantem Capital and other Sydney-based buyers suggest material momentum.
The broader context indicates consolidation fatigue among large institutional capital providers for healthcare M&A in Australia, while smaller private equity firms remain actively engaged in segmented acquisitions within the sector.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.